Living longer, living better, and restoring what biology loses.
Our initial focus is measurable healthspan, the biology of repair, and rigorous translation from laboratory insight to meaningful clinical or commercial outcomes. It is not loose anti-ageing wellness.
Many of the first successful interventions will be developed for specific diseases, measured against clinical endpoints, and only later considered for broader use. Ageing itself does not offer a simple regulatory pathway, and we do not invest as though it does.
The need is real. The World Health Organization expects the number of people aged 60 and over to reach roughly 1.4 billion by 2030 (WHO, Ageing and health). What matters is how many of those years people can spend with physical and cognitive function, independence and a reasonable quality of life.
Three ways of addressing one problem: keeping people healthier for longer by understanding, preserving and restoring biological function.
These tools are only valuable if they change decisions and outcomes. A new score that assigns someone a different biological age is not enough on its own.
Much of medicine works by inhibition. We are especially interested in therapies that activate repair, tested against a well-defined mechanism and a measurable clinical outcome.
The costs, delivery challenges and regulatory requirements are as real as the science. This needs specialist diligence, milestone-based financing and, often, partners for later development.
Therapies are only part of the opportunity. There is considerable value in the systems that help identify a problem, decide which intervention is appropriate, deliver it responsibly and understand whether it worked. We think about four investable layers, each with its own risk profile and timeline.
Mechanism-based medicines that restore or replace function. Value is set by clinical evidence.
Measurement that changes a clinical decision. It depends on reliability, consent and proof that acting on the signal improves care.
The facilities, operating systems and processes that let new interventions be tested, produced and delivered consistently.
Only where outcomes can be measured and the underlying claims withstand scrutiny.
Nothing on this page is medical advice or a claim about the efficacy of any product.
The founding paper sets out why we begin with biology and why the infrastructure between the laboratory and the patient is often where the most company-building work remains.
Read the paper